Skip to main content
. 2020 May 12;10(5):750. doi: 10.3390/biom10050750

Table 6.

Clinical trials involving the combination of immune checkpoint (ICP) and galectin-mediated therapies.

Clinical Trial Numbers Title Status Targets Tumor Types Phases Start Date End Date
NCT01723813 Peptide Vaccinations Plus GM-CT-01 in Melanoma Terminated Galectins + Vaccine Metastatic Melanoma Phase 1
Phase 2
April 2012 April 2015
NCT04139902 PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Not yet recruiting TIM-3 + PD-1 Melanoma Phase 2 15 March 2020 15 December 2024
NCT03708328 A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants with Advanced and/or Metastatic Solid Tumors Recruiting TIM-3 + PD-1 Solid Tumors Phase 1 15 October 2018 13 September 2022
NCT02575404 GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients Recruiting Galectins (esp. Gal-3) + PD-1 Various Phase 1 16 May 2016 October 2021
NCT02117362 Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients with Metastatic Melanoma Completed Galectins (esp. Gal-3) + PD-1 Metastatic Melanoma Phase 1 8 May 2014 28 November 2018